ARRANON G（ネララビン）注射剤250mgの薬物使用調査

基本情報

NCT ID

NCT01376115

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

343

治験依頼者名

Novartis

概要

To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases: 1. T-cell acute lymphocytic leukemia (T-ALL) 2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological disorder, hypotension, and blood disorder and their details" are to be investigated as an item of particular concern. In addition, subject outcome (alive or dead) at one year after the start of treatment will also be investigated.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)